RVXCF (Resverlogix) Cash And Cash Equivalents : $0.10 Mil (As of Dec. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Resverlogix Cash And Cash Equivalents?

Resverlogix's quarterly cash and cash equivalents declined from Jun. 2024 ($0.06 Mil) to Sep. 2024 ($0.04 Mil) but then increased from Sep. 2024 ($0.04 Mil) to Dec. 2024 ($0.10 Mil).

Resverlogix's annual cash and cash equivalents declined from Dec. 2022 ($0.04 Mil) to Dec. 2023 ($0.01 Mil) but then increased from Dec. 2023 ($0.01 Mil) to Dec. 2024 ($0.10 Mil).

Resverlogix Cash And Cash Equivalents Historical Data

The historical data trend for Resverlogix's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Resverlogix Cash And Cash Equivalents Chart

Resverlogix Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

Get a 7-Day Free Trial

0.01

0.04

0.01

0.10

Resverlogix Quarterly Data
	Jan20	Apr20	Jul20	Oct20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Cash And Cash Equivalents	Get a 7-Day Free Trial															0.01	0.06	0.06	0.04	0.10

Resverlogix Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Resverlogix (OTCPK:RVXCF) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Resverlogix Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Resverlogix's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Resverlogix Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Resverlogix Corp (OTCPK:RVXCF) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

RVX:Canada

Address

4820 Richard Road South West, Suite 300, Calgary, AB, CAN, T3E 6L1

Website

https://www.resverlogix.com

Resverlogix Corp clinical-stage biotechnology company. The company is developing apabetalone (RVX-208), a first-in-class, small molecule that is a selective BET (bromodomain and extra terminal) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. Apabetalone is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. This selective inhibition of apabetalone on BD2 produces a specific set of biological effects with potentially important benefits for patients with chronic disease including cardiovascular disease (CVD) and associated comorbidities, and COVID-19.